Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

Kymera Therapeutics, a clinical-stage biopharmaceutical company, has released updated clinical data from the phase 1 trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413. The new data shows that both programs continue to demonstrate substantial target knockdown in ongoing clinical trials with no dose limiting toxicities observed. Kymera is developing these drugs to target protein degrada..